---
schema_version: "secwatch.filing_event.v1"
accession: "0000950157-22-001253"
form_type: "8-K"
ticker: "VTRS"
cik: "0001792044"
company_name: "Viatris Inc"
filed_at: "2022-11-29T23:59:59+00:00"
generated_at: "2026-06-21T12:22:50.112964+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Viatris closes $3.335B biosimilars sale to Biocon Biologics; receives $2B cash and 12.9% equity stake

## Summary
- Total consideration: $2B cash at close, $1B convertible preferred equity (12.9% stake), plus $335M in future cash payments in 2024.
- 2022 revenue expected ~$80M lower and adjusted EBITDA ~$20M lower due to transaction; ~$400M in deal-related expenses incurred.
- Net proceeds to be used to pay down short-term debt, fund ~$700-750M ophthalmology acquisitions (Q1 2023), and initiate share buybacks in 2023.
- Viatris and Biocon Biologics entered a 2-year Transition Services Agreement for business continuity.

## SEC filing metadata
- accession: 0000950157-22-001253
- form_type: 8-K
- ticker: VTRS
- cik: 0001792044
- company_name: Viatris Inc
- filed_at: 2022-11-29T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 2.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1792044/000095015722001253/0000950157-22-001253-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1792044/000095015722001253/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950157-22-001253
- JSON: https://secwatch.observer/filing/0000950157-22-001253.json
- Plain text: https://secwatch.observer/filing/0000950157-22-001253.txt

## Key facts
- M&A Transactions
  Viatris Inc completed a disposition involving Biocon Biologics Limited for $3.335 billion on a cash-free, debt-free basis, consisting of (a) $2.0 billion in cash consideration at closing, subject to certain adjustments as set forth in (closed 2022-11-28).
  - Action: disposition
  - Counterparty: Biocon Biologics Limited
  - Consideration: $3.335 billion on a cash-free, debt-free basis, consisting of (a) $2.0 billion in cash consideration at closing, subject to certain adjustments as set forth in
  - Closing: 2022-11-28
  source text: On November 29, 2022, Viatris Inc., a Delaware corporation (“ Viatris ”), announced that it closed the previously announced transaction with Biocon Biologics Limited, a public limited company incorporated under the India Companies Act, 2013 (“ Biocon Biologics ”), involving the transfer by Viatris of substantially all of its biosimilars portfolio (the “ Biosimilars Business ”) to Biocon Biologics and its subsidiaries (the “ Transaction ”) in exchange for consideration from Biocon Biologics and its subsidiaries of $3.335 billion on a cash-free, debt-free basis, consisting of (a) $2.0 billion in cash consideration at closing, subject to certain adjustments as set forth in the Transaction Agreement (as defined below), (b) a convertible preferred equity stake in Biocon Biologics initially representing 12.9% of the equity in Biocon Biologics (on a fully diluted basis), which the parties’ valued at $1 billion in the Transaction, (c) $160.0 million in future cash consideration, payable on the
  evidence_url: https://www.sec.gov/Archives/edgar/data/1792044/000095015722001253/0000950157-22-001253-index.htm
- Material Agreements
  Viatris Inc amended Amendment No. 1 with Biocon Biologics Limited (effective 2022-11-28).
  - Action: amendment
  - Agreement: asset purchase
  - Counterparty: Biocon Biologics Limited
  - Effective: 2022-11-28
  source text: On November 28, 2022, prior to the closing of the Transaction, Viatris and Biocon Biologics entered into Amendment No. 1 (" Amendment No. 1 ") to the Transaction Agreement, dated as of February 27, 2022, between Viatris and Biocon Biologics
  evidence_url: https://www.sec.gov/Archives/edgar/data/1792044/000095015722001253/0000950157-22-001253-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.